NCT01796535

Brief Summary

This is a multi-center, non-randomized post marketing surveillance registry including up to 125 patients treated with the PerX360º System™. Patients will receive a follow-up evaluation at the per physician defined time points: at discharge, an Interim 1 visit (1 month), an Interim 2 visit (3-6 months) and a Final visit (12 months). Imaging obtained at visits should be per standard of care.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
125

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2012

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 10, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 21, 2013

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

March 15, 2013

Status Verified

March 1, 2013

Enrollment Period

7 months

First QC Date

December 10, 2012

Last Update Submit

March 13, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Fusion

    Image Assessment

    1 year

Study Arms (1)

PerX360º System™

Patients treated with PerX360º System™

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult subjects treated with the Optiport™ and Opticage™ products

You may qualify if:

  • Patient understands the nature of the procedure and provides written informed consent
  • Patient is willing to return to the treating physician for his/her routine follow-up visits up to 12 months post treatment
  • Age \> 18 years
  • Patient is treated with the Optiport™ and Opticage™ products

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Los Angeles Brain and Spine Institute

Los Angeles, California, 90036, United States

RECRUITING

Flagler Hospital

Saint Augustine, Florida, 32086, United States

RECRUITING

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Target Duration
1 Year
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 10, 2012

First Posted

February 21, 2013

Study Start

November 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

March 15, 2013

Record last verified: 2013-03

Locations